Psychomotor performance in relation to acute oral administration of Delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects
Abnormalities in psychomotor performance are a consistent finding in schizophrenic patients as well as in chronic cannabis users. The high levels of central cannabinoid (CB(1)) receptors in the basal ganglia, the cerebral cortex and the cerebellum indicate their implication in the regulation of moto...
Saved in:
Published in | European archives of psychiatry and clinical neuroscience Vol. 259; no. 5; p. 284 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Germany
01.08.2009
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Abnormalities in psychomotor performance are a consistent finding in schizophrenic patients as well as in chronic cannabis users. The high levels of central cannabinoid (CB(1)) receptors in the basal ganglia, the cerebral cortex and the cerebellum indicate their implication in the regulation of motor activity. Based on the close relationship between cannabis use, the endogenous cannabinoid system and motor disturbances found in schizophrenia, we expected that administration of cannabinoids may change pattern of psychomotor activity like in schizophrenic patients. This prospective, double-blind, placebo-controlled cross-over study investigated the acute effects of cannabinoids on psychomotor performance in 24 healthy right-handed volunteers (age 27.9 +/- 2.9 years, 12 male) by comparing Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and standardized cannabis extract containing Delta(9)-THC and cannabidiol. Psychomotor performance was assessed by using a finger tapping test series. Cannabis extract, but not Delta(9)-THC, revealed a significant reduction of right-hand tapping frequencies that was also found in schizophrenia. As to the pure Delta(9)-THC condition, left-hand tapping frequencies were correlated with the plasma concentrations of the Delta(9)-THC metabolite 11-OH-THC. These effects are thought to be related to cannabinoid actions on CB(1) receptors in the basal ganglia, the cerebral cortex and the cerebellum. Our data further demonstrate that acute CB(1) receptor activation under the cannabis extract condition may also affect intermanual coordination (IMC) as an index of interhemispheric transfer. AIR-Scale scores as a measure of subjective perception of intoxication were dose-dependently related to IMC which was shown by an inverted U-curve. This result may be due to functional changes involving GABAergic and glutamatergic neurotransmission within the corpus callosum. |
---|---|
AbstractList | Abnormalities in psychomotor performance are a consistent finding in schizophrenic patients as well as in chronic cannabis users. The high levels of central cannabinoid (CB(1)) receptors in the basal ganglia, the cerebral cortex and the cerebellum indicate their implication in the regulation of motor activity. Based on the close relationship between cannabis use, the endogenous cannabinoid system and motor disturbances found in schizophrenia, we expected that administration of cannabinoids may change pattern of psychomotor activity like in schizophrenic patients. This prospective, double-blind, placebo-controlled cross-over study investigated the acute effects of cannabinoids on psychomotor performance in 24 healthy right-handed volunteers (age 27.9 +/- 2.9 years, 12 male) by comparing Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and standardized cannabis extract containing Delta(9)-THC and cannabidiol. Psychomotor performance was assessed by using a finger tapping test series. Cannabis extract, but not Delta(9)-THC, revealed a significant reduction of right-hand tapping frequencies that was also found in schizophrenia. As to the pure Delta(9)-THC condition, left-hand tapping frequencies were correlated with the plasma concentrations of the Delta(9)-THC metabolite 11-OH-THC. These effects are thought to be related to cannabinoid actions on CB(1) receptors in the basal ganglia, the cerebral cortex and the cerebellum. Our data further demonstrate that acute CB(1) receptor activation under the cannabis extract condition may also affect intermanual coordination (IMC) as an index of interhemispheric transfer. AIR-Scale scores as a measure of subjective perception of intoxication were dose-dependently related to IMC which was shown by an inverted U-curve. This result may be due to functional changes involving GABAergic and glutamatergic neurotransmission within the corpus callosum.Abnormalities in psychomotor performance are a consistent finding in schizophrenic patients as well as in chronic cannabis users. The high levels of central cannabinoid (CB(1)) receptors in the basal ganglia, the cerebral cortex and the cerebellum indicate their implication in the regulation of motor activity. Based on the close relationship between cannabis use, the endogenous cannabinoid system and motor disturbances found in schizophrenia, we expected that administration of cannabinoids may change pattern of psychomotor activity like in schizophrenic patients. This prospective, double-blind, placebo-controlled cross-over study investigated the acute effects of cannabinoids on psychomotor performance in 24 healthy right-handed volunteers (age 27.9 +/- 2.9 years, 12 male) by comparing Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and standardized cannabis extract containing Delta(9)-THC and cannabidiol. Psychomotor performance was assessed by using a finger tapping test series. Cannabis extract, but not Delta(9)-THC, revealed a significant reduction of right-hand tapping frequencies that was also found in schizophrenia. As to the pure Delta(9)-THC condition, left-hand tapping frequencies were correlated with the plasma concentrations of the Delta(9)-THC metabolite 11-OH-THC. These effects are thought to be related to cannabinoid actions on CB(1) receptors in the basal ganglia, the cerebral cortex and the cerebellum. Our data further demonstrate that acute CB(1) receptor activation under the cannabis extract condition may also affect intermanual coordination (IMC) as an index of interhemispheric transfer. AIR-Scale scores as a measure of subjective perception of intoxication were dose-dependently related to IMC which was shown by an inverted U-curve. This result may be due to functional changes involving GABAergic and glutamatergic neurotransmission within the corpus callosum. Abnormalities in psychomotor performance are a consistent finding in schizophrenic patients as well as in chronic cannabis users. The high levels of central cannabinoid (CB(1)) receptors in the basal ganglia, the cerebral cortex and the cerebellum indicate their implication in the regulation of motor activity. Based on the close relationship between cannabis use, the endogenous cannabinoid system and motor disturbances found in schizophrenia, we expected that administration of cannabinoids may change pattern of psychomotor activity like in schizophrenic patients. This prospective, double-blind, placebo-controlled cross-over study investigated the acute effects of cannabinoids on psychomotor performance in 24 healthy right-handed volunteers (age 27.9 +/- 2.9 years, 12 male) by comparing Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and standardized cannabis extract containing Delta(9)-THC and cannabidiol. Psychomotor performance was assessed by using a finger tapping test series. Cannabis extract, but not Delta(9)-THC, revealed a significant reduction of right-hand tapping frequencies that was also found in schizophrenia. As to the pure Delta(9)-THC condition, left-hand tapping frequencies were correlated with the plasma concentrations of the Delta(9)-THC metabolite 11-OH-THC. These effects are thought to be related to cannabinoid actions on CB(1) receptors in the basal ganglia, the cerebral cortex and the cerebellum. Our data further demonstrate that acute CB(1) receptor activation under the cannabis extract condition may also affect intermanual coordination (IMC) as an index of interhemispheric transfer. AIR-Scale scores as a measure of subjective perception of intoxication were dose-dependently related to IMC which was shown by an inverted U-curve. This result may be due to functional changes involving GABAergic and glutamatergic neurotransmission within the corpus callosum. |
Author | Gorynia, Inge Roser, Patrik Gallinat, Jürgen Weinberg, Gordon Stadelmann, Andreas M Juckel, Georg |
Author_xml | – sequence: 1 givenname: Patrik surname: Roser fullname: Roser, Patrik email: patrik.roser@rub.de organization: Department of Psychiatry, Ruhr-University Bochum, Bochum, Germany. patrik.roser@rub.de – sequence: 2 givenname: Jürgen surname: Gallinat fullname: Gallinat, Jürgen – sequence: 3 givenname: Gordon surname: Weinberg fullname: Weinberg, Gordon – sequence: 4 givenname: Georg surname: Juckel fullname: Juckel, Georg – sequence: 5 givenname: Inge surname: Gorynia fullname: Gorynia, Inge – sequence: 6 givenname: Andreas M surname: Stadelmann fullname: Stadelmann, Andreas M |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19224107$$D View this record in MEDLINE/PubMed |
BookMark | eNpNkE1LxDAQhoOsuOvqD_AiOXmrTpp-HmX9hAU97L2kzYRmaZOapGD9K_5ZK7uCl5nhfR_mZeacLIw1SMgVg1sGkN95gASyCKCMoMiKKD0hK5ZwHhVJyRb_5iU5934PACyN4YwsWRnHCYN8Rb7f_dS0trfBOjqgU9b1wjRItaEOOxG0NTRYKpoxILVOdFTIXhvtgzuYVtEH7IIoo4Cz1k7S2UYYI2pt7EwbSX2Yq3BSf6GkR89T_JzxJvwmtSi60E60Hedw6sd6j03wF-RUic7j5bGvye7pcbd5ibZvz6-b-200pEkelTLleS0hUzwGyWSSchQFxHHJIZYKBatVzmJWqkzN1zPFZCqB17KWKPI84Wtyc1g7OPsxog9Vr32DXScM2tFXWc4KBgxm8PoIjnWPshqc7oWbqr9v8h_gEX1p |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1007/s00406-009-0868-5 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 1433-8491 |
ExternalDocumentID | 19224107 |
Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -Y2 .86 .GJ .VR 06C 06D 0R~ 0VY 1N0 2.D 203 28- 29G 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3O- 4.4 406 408 409 40D 40E 53G 5GY 5QI 5RE 5VS 67Z 6NX 7X7 88E 8AO 8FI 8FJ 8UJ 95- 95. 95~ 96X AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AAPKM AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBRH ABBXA ABDBE ABDBF ABDZT ABECU ABFSG ABFTV ABHLI ABHQN ABIPD ABIVO ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABRTQ ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACSTC ACUDM ACUHS ACZOJ ADBBV ADHIR ADHKG ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AEZWR AFBBN AFDZB AFEXP AFFNX AFHIU AFKRA AFLOW AFOHR AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGQPQ AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHPBZ AHSBF AHWEU AHYZX AIAKS AIGIU AIIXL AILAN AITGF AIXLP AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AOCGG ARMRJ ATHPR AXYYD AYFIA AZFZN AZQEC B-. B0M BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BSONS BVXVI CAG CCPQU CGR COF CS3 CSCUP CUY CVF DDRTE DL5 DNIVK DPUIP DU5 DWQXO EAD EAP EBC EBD EBLON EBS ECM EIF EIOEI EJD EMB EMK EMOBN EN4 EPL EPS ESBYG ESX F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNUQQ GNWQR GQ7 GQ8 GRRUI GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ IAO IHE IHR IJ- IKXTQ IMOTQ IPY ITC ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M2M M4Y MA- N2Q N9A NB0 NDZJH NPM NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P9S PF0 PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PSYQQ PT4 PT5 Q2X QOK QOR QOS R89 R9I RHV RIG RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TSG TSK TSV TT1 TUC TUS U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 YLTOR Z45 ZMTXR ZOVNA ZXP ~8M ~EX 7X8 |
ID | FETCH-LOGICAL-p547-9d537bd06f320d1d453ea80229302dfea1bf71219f6f5201f1d5d03bdbdea7743 |
ISSN | 1433-8491 |
IngestDate | Mon Jul 21 10:56:51 EDT 2025 Mon Jul 21 05:31:43 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-p547-9d537bd06f320d1d453ea80229302dfea1bf71219f6f5201f1d5d03bdbdea7743 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
PMID | 19224107 |
PQID | 67181010 |
PQPubID | 23479 |
ParticipantIDs | proquest_miscellaneous_67181010 pubmed_primary_19224107 |
PublicationCentury | 2000 |
PublicationDate | 2009-Aug 20090801 |
PublicationDateYYYYMMDD | 2009-08-01 |
PublicationDate_xml | – month: 08 year: 2009 text: 2009-Aug |
PublicationDecade | 2000 |
PublicationPlace | Germany |
PublicationPlace_xml | – name: Germany |
PublicationTitle | European archives of psychiatry and clinical neuroscience |
PublicationTitleAlternate | Eur Arch Psychiatry Clin Neurosci |
PublicationYear | 2009 |
References | 10729368 - Eur J Pharmacol. 2000 Mar 17;391(3):269-74 10462071 - Life Sci. 1999;65(6-7):703-13 2346396 - Arch Neurol. 1990 Jun;47(6):681-4 18985298 - Eur Arch Psychiatry Clin Neurosci. 2008 Nov;258 Suppl 5:66-70 5146491 - Neuropsychologia. 1971 Mar;9(1):97-113 10501554 - Neuroreport. 1999 Jun 3;10 (8):1665-9 11176943 - Arch Neurol. 2001 Jan;58(1):105-11 11311783 - Neuroscience. 2001;103(1):9-15 15111259 - Neurotox Res. 2001 Jan;3(1):23-35 10484943 - Am J Psychiatry. 1999 Sep;156(9):1342-8 12664316 - Eur Arch Psychiatry Clin Neurosci. 2003 Feb;253(1):53-9 2308954 - Proc Natl Acad Sci U S A. 1990 Mar;87(5):1932-6 12412831 - J Clin Pharmacol. 2002 Nov;42(11 Suppl):11S-19S 11606325 - Br J Pharmacol. 2001 Oct;134(4):845-52 7918699 - Eur Arch Psychiatry Clin Neurosci. 1994;244(1):33-8 2185537 - Schizophr Bull. 1990;16(1):87-95 9778318 - Chem Res Toxicol. 1998 Oct;11(10 ):1209-16 14751433 - Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):355-60 11157424 - Br J Psychiatry. 2001 Feb;178:116-22 4069913 - Percept Mot Skills. 1985 Oct;61(2):479-95 10529019 - Drug Alcohol Depend. 1999 Oct 1;56(3):167-79 3404162 - J Neurol Neurosurg Psychiatry. 1988 May;51(5):626-9 20218784 - World J Biol Psychiatry. 2010 Mar;11(2 Pt 2):208-19 3732341 - Eur Arch Psychiatry Neurol Sci. 1986;235(5):301-8 8194190 - Clin Electroencephalogr. 1994 Apr;25(2):63-75 7738554 - J Neurol Neurosurg Psychiatry. 1995 Apr;58(4):457-61 11408610 - Mol Pharmacol. 2001 Jul;60(1):155-63 6878516 - Psychol Med. 1983 May;13(2):299-306 10397414 - Psychiatry Res. 1999 May 31;86(2):113-29 10689030 - Neuropsychologia. 2000;38(5):529-34 16306858 - Ther Drug Monit. 2005 Dec;27(6):799-810 8748466 - Psychiatry Res. 1995 Nov 10;61(4):209-29 16266285 - Curr Drug Targets CNS Neurol Disord. 2005 Oct;4(5):507-30 7840351 - Am J Psychiatry. 1995 Feb;152(2):191-6 7840889 - Behav Brain Res. 1994 Oct 20;64(1-2):229-40 14324315 - J Am Chem Soc. 1965 Jul 20;87:3273-5 9974180 - Neurobiol Dis. 1998 Dec;5(6 Pt B):483-501 7921721 - Br J Psychiatry. 1994 May;164(5):679-81 18544469 - Eur Neuropsychopharmacol. 2008 Aug;18(8):569-77 10728893 - Cortex. 2000 Feb;36(1):1-18 9130308 - Pharmacol Biochem Behav. 1997 Apr;56(4):803-7 7378515 - Biol Psychiatry. 1980 Jun;15(3):381-8 17884351 - Schizophr Res. 2007 Dec;97(1-3):109-17 17828291 - Br J Pharmacol. 2008 Jan;153(2):199-215 2892048 - Lancet. 1987 Dec 26;2(8574):1483-6 9559936 - Neuroreport. 1998 Mar 9;9(4):671-5 16211466 - Neuropsychol Rev. 2005 Jun;15(2):59-71 2914152 - Biol Psychiatry. 1989 Feb 1;25(3):275-84 17876302 - Br J Pharmacol. 2007 Dec;152(7):1092-101 6948308 - Psychiatry Res. 1981 Dec;5(3):247-55 17349865 - Int Rev Neurobiol. 2007;78:289-326 17131214 - Eur Arch Psychiatry Clin Neurosci. 2007 Jun;257(4):203-10 2165569 - Nature. 1990 Aug 9;346(6284):561-4 12764049 - Brain. 2003 Jun;126(Pt 6):1252-70 10771342 - Neuroscience. 2000;97(1):89-97 1390954 - Eur Arch Psychiatry Clin Neurosci. 1992;242(1):39-45 2608767 - Psychiatry Res. 1989 Sep;29(3):247-53 2669836 - Behav Brain Res. 1989 Aug 1;34(1-2):1-33 |
References_xml | – reference: 10529019 - Drug Alcohol Depend. 1999 Oct 1;56(3):167-79 – reference: 11311783 - Neuroscience. 2001;103(1):9-15 – reference: 2608767 - Psychiatry Res. 1989 Sep;29(3):247-53 – reference: 6948308 - Psychiatry Res. 1981 Dec;5(3):247-55 – reference: 18544469 - Eur Neuropsychopharmacol. 2008 Aug;18(8):569-77 – reference: 2669836 - Behav Brain Res. 1989 Aug 1;34(1-2):1-33 – reference: 3732341 - Eur Arch Psychiatry Neurol Sci. 1986;235(5):301-8 – reference: 15111259 - Neurotox Res. 2001 Jan;3(1):23-35 – reference: 17884351 - Schizophr Res. 2007 Dec;97(1-3):109-17 – reference: 16211466 - Neuropsychol Rev. 2005 Jun;15(2):59-71 – reference: 4069913 - Percept Mot Skills. 1985 Oct;61(2):479-95 – reference: 11176943 - Arch Neurol. 2001 Jan;58(1):105-11 – reference: 3404162 - J Neurol Neurosurg Psychiatry. 1988 May;51(5):626-9 – reference: 17349865 - Int Rev Neurobiol. 2007;78:289-326 – reference: 2185537 - Schizophr Bull. 1990;16(1):87-95 – reference: 2914152 - Biol Psychiatry. 1989 Feb 1;25(3):275-84 – reference: 14324315 - J Am Chem Soc. 1965 Jul 20;87:3273-5 – reference: 10728893 - Cortex. 2000 Feb;36(1):1-18 – reference: 2165569 - Nature. 1990 Aug 9;346(6284):561-4 – reference: 7918699 - Eur Arch Psychiatry Clin Neurosci. 1994;244(1):33-8 – reference: 9130308 - Pharmacol Biochem Behav. 1997 Apr;56(4):803-7 – reference: 12412831 - J Clin Pharmacol. 2002 Nov;42(11 Suppl):11S-19S – reference: 10729368 - Eur J Pharmacol. 2000 Mar 17;391(3):269-74 – reference: 9778318 - Chem Res Toxicol. 1998 Oct;11(10 ):1209-16 – reference: 7840889 - Behav Brain Res. 1994 Oct 20;64(1-2):229-40 – reference: 17828291 - Br J Pharmacol. 2008 Jan;153(2):199-215 – reference: 10771342 - Neuroscience. 2000;97(1):89-97 – reference: 7840351 - Am J Psychiatry. 1995 Feb;152(2):191-6 – reference: 12764049 - Brain. 2003 Jun;126(Pt 6):1252-70 – reference: 9974180 - Neurobiol Dis. 1998 Dec;5(6 Pt B):483-501 – reference: 1390954 - Eur Arch Psychiatry Clin Neurosci. 1992;242(1):39-45 – reference: 10484943 - Am J Psychiatry. 1999 Sep;156(9):1342-8 – reference: 7921721 - Br J Psychiatry. 1994 May;164(5):679-81 – reference: 10462071 - Life Sci. 1999;65(6-7):703-13 – reference: 16306858 - Ther Drug Monit. 2005 Dec;27(6):799-810 – reference: 10501554 - Neuroreport. 1999 Jun 3;10 (8):1665-9 – reference: 11157424 - Br J Psychiatry. 2001 Feb;178:116-22 – reference: 17876302 - Br J Pharmacol. 2007 Dec;152(7):1092-101 – reference: 10689030 - Neuropsychologia. 2000;38(5):529-34 – reference: 12664316 - Eur Arch Psychiatry Clin Neurosci. 2003 Feb;253(1):53-9 – reference: 7378515 - Biol Psychiatry. 1980 Jun;15(3):381-8 – reference: 18985298 - Eur Arch Psychiatry Clin Neurosci. 2008 Nov;258 Suppl 5:66-70 – reference: 9559936 - Neuroreport. 1998 Mar 9;9(4):671-5 – reference: 10397414 - Psychiatry Res. 1999 May 31;86(2):113-29 – reference: 8194190 - Clin Electroencephalogr. 1994 Apr;25(2):63-75 – reference: 20218784 - World J Biol Psychiatry. 2010 Mar;11(2 Pt 2):208-19 – reference: 11606325 - Br J Pharmacol. 2001 Oct;134(4):845-52 – reference: 8748466 - Psychiatry Res. 1995 Nov 10;61(4):209-29 – reference: 2308954 - Proc Natl Acad Sci U S A. 1990 Mar;87(5):1932-6 – reference: 17131214 - Eur Arch Psychiatry Clin Neurosci. 2007 Jun;257(4):203-10 – reference: 7738554 - J Neurol Neurosurg Psychiatry. 1995 Apr;58(4):457-61 – reference: 6878516 - Psychol Med. 1983 May;13(2):299-306 – reference: 16266285 - Curr Drug Targets CNS Neurol Disord. 2005 Oct;4(5):507-30 – reference: 5146491 - Neuropsychologia. 1971 Mar;9(1):97-113 – reference: 14751433 - Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):355-60 – reference: 2892048 - Lancet. 1987 Dec 26;2(8574):1483-6 – reference: 2346396 - Arch Neurol. 1990 Jun;47(6):681-4 – reference: 11408610 - Mol Pharmacol. 2001 Jul;60(1):155-63 |
SSID | ssj0001520 |
Score | 1.8635563 |
Snippet | Abnormalities in psychomotor performance are a consistent finding in schizophrenic patients as well as in chronic cannabis users. The high levels of central... |
SourceID | proquest pubmed |
SourceType | Aggregation Database Index Database |
StartPage | 284 |
SubjectTerms | Administration, Oral Adult Analysis of Variance Cannabidiol - administration & dosage Cannabidiol - pharmacology Cannabinoids - administration & dosage Cannabinoids - pharmacology Cannabis - chemistry Cross-Over Studies Double-Blind Method Dronabinol - administration & dosage Dronabinol - analogs & derivatives Dronabinol - blood Dronabinol - metabolism Dronabinol - pharmacology Female Fingers - physiology Functional Laterality - drug effects Humans Male Neuropsychological Tests Plant Preparations - chemistry Plant Structures - chemistry Psychomotor Performance - drug effects Reference Values |
Title | Psychomotor performance in relation to acute oral administration of Delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects |
URI | https://www.ncbi.nlm.nih.gov/pubmed/19224107 https://www.proquest.com/docview/67181010 |
Volume | 259 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBbb5NJLaekraZvq0FtQsC3bio9NukkI6bYUB_ZmJEumC8EOu95D8lf6d_rDOmNZspdunxezaNmV0XzMQzPfDCHveCBB7euSHYdCslhnhmUiUgycDRUYQIjoGHIfZ-nFdXw5T-aTyfdR1dK6VUfl_VZeyf9IFdZArsiS_QfJ-j-FBfgM8oUnSBiefyVjq73gsJsl9h_2DADPUcFMQHMoy64YAKn4cqNXLnqKH8xNKzPWGlj7eqfBnsm6lhAvN7aJgLtrWNyDa9p_tzoElY70KtzJMinv-ml_q7XCm53V1ht_OWpzO5RZW2qdY2iOGmx6zOH4x6UfKOC5RecSG4pLm03BjP_JKVJJh2TTwlevnUOMPRQcXGIxyY1PCWzcfGS-7s4p65hzdhzbaV9HZstar-Gjvun4YpxEt_razqf7yY7Y0hHsNIsXLt3WyFAbjKYrFJh9Ks6ur66KfDrPH5DdCIIV1LZi7sN-8Le65qD-zVxuPbCtbDc2-HWc0_k7-WPyqA9U6HuLuidkYuqn5NsIcXSEOLqoqUMcbRvaIY4i4ugm4mhT0d8gjgIU6Bhx1CGO9ojDnXrE0Q5x1CHuGcnPpvnpBevHe7DbJBYs0wkXSgdpxaNAhzpOuJFI_M54EOnKyFBVIgSDWqUVnGBYhTrRAVdaaSMhaOHPyU7d1OYloTFY9DAEjSPKCvyrRIKbqo1SaRka8IjFHnnrTrUA7YkpMVmbZr0qUnDNwCgFe-SFPezi1jZ5KSDyAec2EPt__O0r8nBA52uy0y7X5g14qq066IBwQHZPprPPX34AwOOhCQ |
linkProvider | ProQuest |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Psychomotor+performance+in+relation+to+acute+oral+administration+of+Delta9-tetrahydrocannabinol+and+standardized+cannabis+extract+in+healthy+human+subjects&rft.jtitle=European+archives+of+psychiatry+and+clinical+neuroscience&rft.au=Roser%2C+Patrik&rft.au=Gallinat%2C+J%C3%BCrgen&rft.au=Weinberg%2C+Gordon&rft.au=Juckel%2C+Georg&rft.date=2009-08-01&rft.issn=1433-8491&rft.eissn=1433-8491&rft.volume=259&rft.issue=5&rft.spage=284&rft_id=info:doi/10.1007%2Fs00406-009-0868-5&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1433-8491&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1433-8491&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1433-8491&client=summon |